ClinicalTrials.gg
RecruitingNCT06048003ARMIUpdated Dec 26, 2023

Armenian National Registry of Myocardial Infarction

An observational study in ST Elevation Myocardial Infarction, sponsored by Armenian Cardiologists Association. Recruiting at 13 sites in Armenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-26.

Sponsored by Armenian Cardiologists Association · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Study summary

This is a national, multicenter prospective observational study of patients presenting to hospitals in Armenia with STEMI diagnosis.

The main questions it aims to answer are:

  • Determine the rate of in-hospital mortality for the patients with STEMI admitted to the participating hospitals.
  • Compare short and long-term CV and all-cause mortality and hospitalization.
  • Determine how professional guidelines are followed in real-world situations.
Read the detailed description

Although the state program on primary percutaneous coronary intervention in ST elevated myocardial infarction, which was launched in 2015 helped to drastically decrease STEMI mortality rates, patients who had survived usually develop heart failure (HF) which leads to increased economic burden for the Armenian healthcare system.

The total duration of the study will be 24 months. The target number of the inclusion is 2500 patients. The follow-up period for enrolled patients will be 12 months.

02

Conditions studied

  • ST Elevation Myocardial Infarction

Keywords

  • STEMI
  • Myocardial infarction
  • acute coronary syndrome
  • CV mortality
  • biobanking
03

In context

ST Elevation Myocardial Infarction

850 studies on the registry are indexed under ST Elevation Myocardial Infarction; 197 are open to participants now.

This study's planned enrollment of 2,500 is above the median of 335 across 297 observational studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

This is the only study on the registry with Armenian Cardiologists Association as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The pre-screened population will consist of all patients >18 years old presenting acutely with suspected STEMI in the participating hospitals.

Only patients with confirmed diagnosis of STEMI will be included in the registry, after informed consent signing.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patient (≥ 18 years of age),
  2. Admitted to the participating centers for a STEMI within 48 hours of symptom onset: characterized by a rise and fall of cardiac markers (troponins) together with ST elevation in at least two contagious leads or LBBB.
  3. Have given signed to participate in the study.

Non-Inclusion Criteria:

  1. MI occurring ≤ 48 hours after PCI or CABG
  2. The patient or the legal representative refused to sign the informed consent

Exclusion criteria

Exclusion Criteria:

Withdrawal of the

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • OtherNo specific intervention

    No specific intervention

06

What researchers measure

Primary outcomes

  1. Rate of the in-hospital mortality

    Determine the rate of the in-hospital mortality for the patients with STEMI admitted to the participating hospitals

    Time frame: During 5 to 7 days of hospitalization

Secondary outcomes

  1. Cardiovascular mortality

    Compare short-term (30 days) and long-term (12 months) CV mortality depending on the management strategies.

    Time frame: 30 days and 12 months

  2. All-cause mortality

    Compare short-term (30 days) and long-term (12 months) all-cause mortality.

    Time frame: 30 days and 12 months

07

Study locations

13 of 13 sites recruiting
  • Vanadzor Medical Center
    Vanadzor, Lori, Armenia
    Recruiting
    • Inga Hovhannisyan · Contact
  • Gyumri Medical Center
    Gyumri, Shirak, Armenia
    Recruiting
    • Arthur Stepanyan · Contact
  • French-Armenian Cardiovascular Center
    Goris, Syunik, Armenia
    Recruiting
    • Shahane Musayelyan · Contact
  • Heratsi Hospital Complex N1
    Yerevan, 0025, Armenia
    Recruiting
    • Hamayak S Sisakyan · Contact
  • Erebouni Medical Center
    Yerevan, 0087, Armenia
    Recruiting
    • Hamlet G Hayrapetyan · Contact
  • Aramyants Medical Center
    Yerevan, Armenia
    Recruiting
    • Narek Atoyan · Contact
  • Armenia Medical Center
    Yerevan, Armenia
    Recruiting
    • Mayranush Drambyan · Contact
  • Astghik Medical Center
    Yerevan, Armenia
    Recruiting
    • Zara Kartoyan · Contact
  • Best Life Medical Center
    Yerevan, Armenia
    Recruiting
    • Serob Manukian · Contact
  • Nork Marash Medical Center
    Yerevan, Armenia
    Recruiting
    • Mikael Adamyan · Contact
  • Shengavit Medical Center
    Yerevan, Armenia
    Recruiting
    • Tigran Astvatsatryan · Contact
  • Surb Grigor Lusavorich Medical Center
    Yerevan, Armenia
    Recruiting
    • Irina Hovhannisyan · Contact
  • Yerevan Scientific Medical Center
    Yerevan, Armenia
    Recruiting
    • Hovhannes Kzhdryan · Contact
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06048003
Lead sponsor
Armenian Cardiologists Association
Collaborators
Santé Arménie French-Armenian Research Center
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Dec 1, 2023
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Dec 26, 2023

Study contacts

Hamlet G Hayrapetyan, Prof.
Contact
cardioerebouni@yahoo.com
+37493555050
Hripsime V Poghosyan, Dr.
Contact
hripsime.poghosyan@santearmenie.org
+37477234994
Hamlet G Hayrapetyan, Prof.
principal investigator · Armenian Cardiologists Association

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion